Biocytogen’s Subsidiary Eucure Biopharma Signs an Exclusive License Agreement with Chipscreen’s Holding Subsidiary Chipscreen NewWay for YH008
- Eucure Biopharma will receive $5.76M up front, ~$51.84M in development milestones & ~$28.22M in sales milestones along with royalties. The companies collaborated for the clinical development & commercialization of YH008 in Greater China (incl. Mainland China, Hong Kong, Macau & Taiwan)
- Eucure Biopharma holds the rights globally to develop & commercialize YH008 outside Greater China. The agreement will accelerate Chipscreen NewWay’s pipeline in the field of Ab drugs & immuno-oncology
- YH008 is a bispecific Ab that exerts antagonistic & agonistic activities & showed superior anti-tumor activity over parental mAbs or combination therapy in syngeneic models. Comparing YH008 to benchmark mAbs, both in vivo studies & GLP toxicology studies show improved safety
Ref: Businesswire| Image: Biocytogen
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.